Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (2,810,091)	$ (4,379,890)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,157	410
Stockbased compensation	85,830	16,244
Foreign currency (gain) loss	(56,176)	13,797
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	213,641	344,056
Accounts payable	(350,256)	(16,727)
Accrued expenses	(644,427)	1,043,029
Deferred grant revenue	(380,569)
Net cash used in operating activities	(3,935,891)	(2,979,081)
Cash flows from investing activities:
Purchases of property and equipment	(7,978)
Net cash used in investing activities	(7,978)
Cash flows from financing activities:
Proceeds from issuance of common stock	15,999,598	5,788,918
Common stock issuance costs	(1,289,893)	(648,928)
Net cash provided by financing activities	14,709,705	5,139,990
Change in cash and cash equivalents and restricted cash	10,765,836	2,160,909
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2,414)	48,158
Cash, cash equivalents and restricted cash-beginning of year	21,647,537	28,786,647
Cash, cash equivalents and restricted cash-end of period	32,410,959	30,995,714
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	32,369,973	30,995,714
Restricted cash	40,986
Total cash, cash equivalents and restricted cash	$ 32,410,959	$ 30,995,714